 |
Tezacaftor and Ivacaftor combination therapy |
|---|---|
| Trade Name | |
| Orphan Indication | Cystic fibrosis |
| USA Market Approval | USA |
| USA Designation Date | 2017-06-15 00:00:00 |
| Sponsor | Vertex Pharmaceuticals Inc.;50 Northern Avenue;Boston, Massachusetts, 02210 |
Related Access Program